logo-loader
viewCollagen Solutions PLC

Collagen Solutions CEO expects new business to boost full-year revenue, beating market forecasts

Collagen Solutions PLC (LON:COS) CEO Jamal Rushdy tells Proactive Investors the firm expects full-year revenue to beat market forecasts, driven by deals to develop collagen products on behalf of third parties.

Rushdy also says the company is 'anxiously waiting' a CE Mark approval for its product ChondroMimetic, a minimally-invasive surgically placed scaffold that helps to repair knee cartilage.

Quick facts: Collagen Solutions PLC

Price: 3.55 GBX

LSE:COS
Market: LSE
Market Cap: £15.75 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Collagen Solutions PLC named herein, including the promotion by the Company of Collagen Solutions PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Collagen Solutions released financial number showing more...

Collagen Solutions (LON: COS) CEO Jamal Rushdy joined Steve Darling from Proactive to discuss the company releasing their financial numbers that show impressive double-digit sales growth.  Rushdy talks about the numbers and also their tissue division that continues to be a revenue driver.

3 weeks, 2 days ago

2 min read